Abstract:VEGFA is an essential growth factor required for angiogenesis in the context of normal wound healing as well as malignant tissue growth, ultimately facilitating the delivery of oxygen and nutrients to fuel cellular survival, expansion, and repair. VEGFA signaling has also been reported to exert effects on cancer cells and immune cells directly, with evidence suggesting that the pathway can both support tumor growth and inhibit immune surveillance. Thus, targeting VEGFA has been intensely explored as a therapeutic strategy for several cancer indications. Here, we generated a novel humanized VEGFA model (B-hVEGFA mice) to explore the ability of novel VEGFA-targeting therapeutics to curb cancer cell growth and angiogenesis in vivo. This was achieved by replacing the murine Vegfa gene with the corresponding human VEGFA coding region. We confirmed exclusive expression of human VEGF in lung homogenates of the humanized model at levels comparable to murine VEGF quantified in wild-type C57BL/6 mice. Immunohistochemical analysis at 8 weeks of age demonstrates no significant difference in the CD31+ area in several organs of the humanized mice when compared to wild-type C57BL/6 mice, including kidney, heart, liver, and eye. To assess the functional utility of this model in evaluating VEGFA modulators, tumor studies were conducted: murine colon cancer MC38 cells that were also engineered to express VEGFA in a similar manner (B-hVEGFA MC38 cells) were subcutaneously implanted into homozygous B-hVEGFA mice. Treatment with bevacizumab analog essentially abolished tumor growth in the humanized mice, while control tumors continued to expand over the 3 week study. To further evaluate the role of novel combination therapies or bispecific antibodies targeting VEGFA and PD-1, we also generated a triple humanized model expressing human VEGF, PD-1, and PD-L1 (B-hPD-1/hPD-L1/hVEGFA mice) by crossing B-hVEGFA mice with our B-hPD-1/hPD-L1 mice model, which expresses the extracellular domains of human PD-1 and PD-L1. Flow cytometric analysis of this model is currently underway to validate the model for further efficacy testing. Together, these humanized VEGF models provide robust in vivo platforms to evaluate novel VEGFA therapeutic candidates. Citation Format: Shujin Zhang, Chonghui Liu, Jin Guo, Zhiyuan Shen, James Jin, Bahetiyaer Huwatibieke, Yang Shen. Development of humanized VEGFA models to assess preclinical efficacy of novel therapeutics in vivo [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 125.

Expression of VEGFR2 Ligand Binding Domain in Pichia pinkTM 4 Cells and Evaluation of Its Interactions with VEGF-A165 Receptor Binding Domain

Expression of human vascular endothelial growth factor receptor Flt-1 extracellular domain 1-3 loop cDNA in Pichia pastoris, purification of the expressed product and detection of its biological activity.

Discovering Small Molecule Ligands of Vascular Endothelial Growth Factor That Block Vegf-Kdr Binding Using Label-Free Microarray-Based Assays

Cloning and expression of truncated KDR binding to vascular endothelial growth factor

[Expression and Characterization of Human Vascular Endothelial Growth Factor in Pichia Pastoris].

Targeted Delivery of Diphtheria Toxin into VEGFR1/VEGFR2 Overexpressing Cells Induces Anti-angiogenesis Activity

Synthesis and Biological Evaluation of Glycyrrhetic Acid Derivatives As Potential VEGFR2 Inhibitors

VEGF165 Modulates Proliferation, Adhesion, Migration and Differentiation of Cultured Human Outer Root Sheath Cells from Central Hair Follicle Epithelium Through VEGFR-2 Activation in Vitro

High-yield expression of human vascular endothelial growth factor VEGF(165) in Escherichia coli and purification for therapeutic applications

Optimizing dosage regimen for FP 3 based on vascular normalization window monitored by ratio of Ang-1 to Ang-2

Expression of VEGFR-2 on HaCaT Cells is Regulated by VEGF and Plays an Active Role in Mediating VEGF Induced Effects

Expression of VEGF Receptor KDR in Different Originated Carcinomas

Discovery of VEGF-KDR Binding Inhibitors by Screening Small-Molecule Microarrays with Label-Free Ellipsometric Scanners

Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer

A Peptide Fusion Protein Inhibits Angiogenesis and Tumor Grow- Th by Blocking VEGF Binding to KDR

Quantitative Determination of Vegf165 in Cell Culture Medium by Aptamer Sandwich Based Chemiluminescence Assay

Inhibition of Vascular Smooth Muscle and Cancer Cell Proliferation by New VEGFR Inhibitors and Their Immunomodulator Effect: Design, Synthesis, and Biological Evaluation

Abstract 125: Development of humanized VEGFA models to assess preclinical efficacy of novel therapeutics in vivo

Screening and Characterization of Inhibiting Peptides Binding to the Tumor Vascular Growth Factor Receptor

A Novel Peptide Isolated from a Phage Display Library Inhibits Tumor Growth and Metastasis by Blocking the Binding of Vascular Endothelial Growth Factor to Its Kinase Domain Receptor.

Preparation of human vascular endothelial growth factor-D for structural and preclinical therapeutic studies